All terms in DRUGBANK

Label Id Description
N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE DB08018
Streptococcus pneumoniae type 19f capsular polysaccharide antigen DB10336 [Streptococcus pneumoniae type 19f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19f of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
2'-cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine DB11667 [2'-cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine has been used in trials studying the treatment of Advanced Colorectal Cancer.]
N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine DB08019
Buparlisib DB11666 [Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.]
Streptococcus pneumoniae type 18c capsular polysaccharide antigen DB10335 [Streptococcus pneumoniae type 18c capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 18c of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
Brilacidin DB12997 [Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.]
PF-00217830 DB12998 [PF-00217830 has been used in trials studying the treatment of Schizophrenia.]
MK-6186 DB12999 [MK6186 has been used in trials studying the treatment of HIV-1 Infection.]
Streptococcus pneumoniae type 22f capsular polysaccharide antigen DB10339 [Streptococcus pneumoniae type 22f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 22f of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
Berkelium DB12993 [Berkelium is under investigation in clinical trial NCT02189122 (Comparative Effects of Aspirin and NHP-544C).]
Streptococcus pneumoniae type 11a capsular polysaccharide antigen DB10330 [Streptococcus pneumoniae type 11a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 11a of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
Eptacog alfa pegol (activated) DB11661 [Eptacog alfa pegol (activated) has been used in trials studying the prevention and treatment of Haemophilia A, Haemophilia B, Congenital Bleeding Disorder, Haemophilia B With Inhibitors, and Haemophilia A With Inhibitors.]
Latanoprostene bunod DB11660 [Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for proposed tissue/cell relaxation effects. In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.]
MIP-1095 I-123 DB12994 [123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).]
Acteoside DB12996 [Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).]
Streptococcus pneumoniae type 17f capsular polysaccharide antigen DB10334 [Streptococcus pneumoniae type 17f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 17f of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
BMS-690514 DB11665 [BMS-690514 has been investigated for the treatment of Breast Cancer.]
Streptococcus pneumoniae type 15b capsular polysaccharide antigen DB10333 [Streptococcus pneumoniae type 15b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 15b of *Streptococcus pneumoniae*. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.]
Psilocybin DB11664 [Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.]